B+
Bull case
30%
Probability
Target price
$2.90
Analysis reference price unavailable
Analysis 2026-10-25 · RankAlpha Sentiment Codex
FBIO
Fortress BiotechANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Q2 consolidated revenue rose 14% to $18.7 million; the company reported $196.6 million in consolidated cash at June 30, including $153.8 million attributable to Fortress and private subsidiaries. Pipeline progress and Journey Medical's Emrosi commercialization could add value, but subsidiary and partner economics must be distinguished from direct Fortress ownership.
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.2.
What can break
Anselamimab did not meet the overall CARES Phase 3 primary endpoint; regulatory acceptance of subgroup findings is uncertain. [#SEC-8K-2026-08-13] Fortress Q2 release
Momentum
91
Value
68
Sentiment
64
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $2.05 · Bull $2.90 · Bear $0.95Analysis 2026-10-25; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-25 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $5.00
Why
Momentum91 · Δ7d -
Value68 · Δ7d -0.2
Sentiment64 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta -0.2.
Contradictions & invalidation
- • Anselamimab did not meet the overall CARES Phase 3 primary endpoint; regulatory acceptance of subgroup findings is uncertain. [#SEC-8K-2026-08-13] Fortress Q2 release
- • Clinical readout failure or delay and trial-initiation slippage could cause disproportionate small-cap volatility.
- • Triplex data and MB-109 timing are uncertain.
Catalyst clock
2026-09-30
Completed secured-debt repayment
Lead driver: Value · See fundamentals
Momentum
91
8% active weight
Current posture
7d trendSoftening
Δ7d
-
Δ21d
-
Value
68
47% active weight
Current posture
7d trendFlat
Δ7d
-0.2
Δ21d
-0.8
Sentiment
64
45% active weight
Current posture
7d trendImproving
Δ7d
-
Δ21d
-
Why this grade
Composite grade A. Momentum 91.4 / Value 68.5 / Sentiment 64.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-25. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$2.05
Analysis reference price unavailable
Analysis 2026-10-25 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$0.95
Analysis reference price unavailable
Analysis 2026-10-25 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$64.37M
Beta
1.44
Shares Out
33.35M
P/E (TTM) · Derived
-28.6
P/S (TTM)
2.13
P/FCF (TTM) · Derived
0.72
Rev YoY
+14.0%
EPS YoY
-117.4%
Gross Margin
+58.9%
Op Margin
-42.9%
Net Debt
-$12.17M
Current Ratio
3.96
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data